Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by Monte Rosa Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Monte Rosa Therapeutics, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:09 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336711
| (in thousands, except share and per share amounts) | Three months ended June 30, 2026 | Three months ended June 30, 2025 | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|---|---|
| Collaboration revenue | $8,968 | $23,194 | $13,178 | $108,123 |
| Operating expenses: | ||||
| Research and development | 47,964 | 30,653 | 92,033 | 62,843 |
| General and administrative | 10,134 | 8,095 | 20,309 | 16,798 |
| Total operating expenses | 58,098 | 38,748 | 112,342 | 79,641 |
| (Loss) income from operations | (49,130) | (15,554) | (99,164) | 28,482 |
| Other income: | ||||
| Interest income | 5,916 | 3,068 | 11,507 | 6,507 |
Item 1. Financial Statements
FAQ
- What is Monte Rosa Therapeutics, Inc.'s R&D?
- Monte Rosa Therapeutics, Inc. (GLUE) reported R&D of $47.96M in Q2 2026.
- How has Monte Rosa Therapeutics, Inc.'s R&D changed year-over-year?
- Monte Rosa Therapeutics, Inc.'s R&D increased by 56.5% year-over-year, from $30.65M to $47.96M.
- What is the long-term trend for Monte Rosa Therapeutics, Inc.'s R&D?
- Over 4 years (2021 to 2025), Monte Rosa Therapeutics, Inc.'s R&D has grown at a 25.4% compound annual growth rate (CAGR), from $57.16M to $141.5M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Monte Rosa Therapeutics, Inc.'s r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude